(landmark ed) 2022; 27(10): characterization of the antibody-drug conjugate trastuzumab

HIGHLIGHTS

• who: (ADC et al. from the de Spectromu00e9trie de Masse BioOrganique, IPHC UMR, Universitu00e9 de Strasbourg, CNRS, Strasbourg, France , Strasbourg Drug Discovery and Development Institute (IMS), University of Strasbourg, Strasbourg, France have published the research work: (Landmark Ed) 2022u037e 27(10): Characterization of the Antibody-Drug Conjugate Trastuzumab, in the Journal: (JOURNAL)
• what: This work provides an overview of the state-of-the-art chromatographic tools available for the detailed characterization of monoclonal antibody (mAb) formats exemplified on the antibody-drug conjugate (ADC) trastuzumab (T-DXd).
• how: This result is in good agreement . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.